Lupin Limited

NSE: LUPIN

Pharma Pharmaceuticals

₹2,225

-0.31%EOD · 19 Aug

Lupin Limited is a listed Pharmaceuticals company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap

₹1.02 L Cr

52W Range

₹2530 / ₹1875

Volume

781K

67.7% delivery

1Y Return

+11.0%

P/E Ratio

18.5

P/B Ratio

4.5

ROE

26.9%

Debt / Equity

29.39

Peers in Pharma

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
Lupin Limited(this stock)	₹2,225	₹1.02 L Cr	18.5	4.5	26.9%	0.80%
Sun Pharmaceutical Industries LimitedSUNPHARMA	₹1,900	₹4.56 L Cr	38.3	5.5	14.7%	0.83%
Cipla LimitedCIPLA	₹1,422	₹1.15 L Cr	34.8	3.4	11.7%	0.89%
Dr. Reddy's Laboratories LimitedDRREDDY	₹1,170	₹97,461 Cr	30.2	2.6	8.8%	0.66%

Technical Indicators

Full analysis · objective math, not advice

Returns

-0.3%

-1.1%

-6.1%

-1.9%

-3.2%

+11.0%

Weinstein Stage

Stage 3 — Topping (distribution)

RSI (14)

17 Oversold

Trend Template

4/7moderate

RS vs Nifty (3M)

-3.4pp

Moving Averages (price vs MA)

20-DMA

₹2335

below

50-DMA

₹2395

below

150-DMA

₹2327

below

200-DMA

₹2280

below

From 52W High

-12.0%

From 52W Low

+17.1%

Support (20D)

₹2203

Resistance (20D)

₹2475

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Quality Signals

Multi-year consistency · Source: Screener annual data

ROE Consistency

0/0 years ≥15%

Revenue Growth

+6.5% CAGR

Up 8 of last 11 years

Earnings Quality

Mostly cash-backed

OCF / Net Profit = 0.87x · 12/12 yrs +ve cash flow

Quality signals derived from multi-year annual financials. ROE consistency = years with ≥15% return on equity. Cash-backed = operating cash flow vs reported net profit (≥1x means earnings are converted to real cash, not just accruals). Educational reference only — not investment advice.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.